Compare WILC & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | IVVD |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.3M | 437.1M |
| IPO Year | 2001 | 2021 |
| Metric | WILC | IVVD |
|---|---|---|
| Price | $28.22 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.2K | ★ 3.4M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $14.22 | $0.49 |
| 52 Week High | $31.16 | $3.07 |
| Indicator | WILC | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 55.73 |
| Support Level | $27.24 | $1.41 |
| Resistance Level | $28.66 | $1.77 |
| Average True Range (ATR) | 0.64 | 0.15 |
| MACD | 0.32 | 0.05 |
| Stochastic Oscillator | 76.74 | 83.33 |
G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.